| Document |
Document Title |
|
WO/2024/050858A1 |
A malignant human breast phyllodes tumor cell strain, a filial generation cell line thereof, and use thereof. The cell line is named malignant human breast phyllodes tumor cell line SYSH-MPT-04, and is deposited under CCTCC NO. C2022190 ...
|
|
WO/2024/052485A1 |
The invention is based on the use of mitophagy agonists as defined in the claims, in particular Urolithin A, for improving mitochondrial health in immune cells such as T-cells. The invention provides new strategies to enhance immune cell...
|
|
WO/2024/049158A1 |
The objective of the present invention is to provide a method for effectively isolating and proliferating stem cells from the peripheral blood. A composition according to the present invention comprises interferon-gamma (IFN-γ) so as to...
|
|
WO/2024/046239A1 |
The present invention relates to a specific recombinant humanized monoclonal antibody targeting human GPRC5D and an application thereof, can be used in ELISA and flow detection methods, and can be used for diagnosis and treatment targeti...
|
|
WO/2024/046329A1 |
Provided is a composition including stem cell is derived from amniotic fluid of an artiodactyl animal. Also provided relates to uses of the composition for skin rejuvenation, skin treatment, promoting hair growth, and preventing hair los...
|
|
WO/2024/049348A1 |
The present invention provides a modified immune cell, which comprises a T cell receptor (TCR) capable of specifically targeting hepatitis B surface antigen (HBsAg) and a chimeric conversion receptor. The chimeric conversion receptor use...
|
|
WO/2024/048899A1 |
The present invention relates to a pharmaceutical composition for alleviating or treating sequelae of cerebral infarction, comprising glia-like cells differentiated from a human mesenchymal stem cell (hMSC). The pharmaceutical compositio...
|
|
WO/2024/048418A1 |
Provided is a diagnostic antibody that is capable of detecting PD-L1 in tumors for novel therapies for feline tumors targeting PD-1/PD-L1. The anti-PD-L1 antibody contains: (a) an L-chain having CDR1 that has the amino acid sequence ES...
|
|
WO/2024/046072A1 |
Disclosed are an immune cell having membrane-bound IL-21 (mbIL-21), and a preparation method therefor and a use thereof. Specifically, disclosed are mbIL-21 and a use thereof in immunotherapy. mbIL-21 can enhance the expansion capability...
|
|
WO/2024/050517A1 |
This invention relates to methods of producing reprogrammed B cells, methods of treating cancer, and methods of enhancing an immune response in a subject having, suspected to have and/or at risk of cancer. The invention further relates t...
|
|
WO/2023/026194A9 |
The present disclosure is directed to a novel sequence constructed from viral elements for use as a transgenic promoter; for example, in transgenic plants. More specifically, the present disclosure is directed to a chimeric transgenic pr...
|
|
WO/2024/046384A1 |
The present invention relates to an antibody specifically binding to a TSHR or an antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, a nucleic acid molecule enc...
|
|
WO/2024/050399A1 |
Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-do...
|
|
WO/2024/050546A1 |
Disclosed herein include methods, compositions and culture media for generating synthetic embryos in vitro from mammalian pluripotent stem cells such as pluripotent embryonic stem cells. In some embodiments, the method can comprise co-cu...
|
|
WO/2024/046355A1 |
Use of a composition including mesenchymal stem cells in the manufacture of a medicament for alleviating myelofibrosis in a subject is provided.
|
|
WO/2024/048731A1 |
Naïve pluripotent stem cells are produced at high efficiency. A method for producing naïve pluripotent stem cells, wherein the method includes the following steps: (1) a step that cultures primed pluripotent stem cells in primed pl...
|
|
WO/2024/045890A1 |
The present invention provides a preparation method for dendritic cell progenitors and a culture medium thereof, and particularly provides a method for preparing dendritic cell progenitors, comprising the step of: culturing cells from pe...
|
|
WO/2024/049713A1 |
Improved nerve regeneration scaffolds are disclosed, which include a plurality of modified nanotube yarn bundles disposed of within the scaffold lumen. The modified nanotube yarn bundles have enhanced hydrophilicity and water absorption....
|
|
WO/2024/047110A1 |
The present invention relates to a new method to obtain more effective CAR-T cells. Here, the inventors worked on the function of FOXO1 in T lymphocyte physiology for many years. They recently described, using a FOXO1 pharmacological inh...
|
|
WO/2024/049658A1 |
A method for functionalizing a hollow-fiber membrane for cell expansion of targeted cells (e.g., natural killer cells) includes contacting a biotinylating molecule to a surface of the hollow-fiber membrane including an extracellular matr...
|
|
WO/2024/050534A2 |
Disclosed are CD34+ hematopoietic stem progenitor cells (HSPCs) generated from induced pluripotent stem cells (iPSCs) and T cells generated from iPSCs under minimal cytokine conditions, and methods of generating and using the same for th...
|
|
WO/2024/045404A1 |
Provided are a bone marrow supernatant and use thereof in stem cell culture. The bone marrow supernatant is obtained by means of treating a bone marrow sample of a newborn mammal, is used as a culture medium additive for cell culture, ca...
|
|
WO/2024/050555A1 |
Disclosed herein include methods and compositions for use in generating synthetic embryos. In some embodiments, the method comprises culturing stem cells that over-express at least one Cadherin.
|
|
WO/2024/044852A1 |
Described herein is a high-throughput method of synthesizing biofunctional microparticles. In aspects, the method comprises casting biofunctional microparticle precursors onto a microporous template to form microparticles, wherein the te...
|
|
WO/2024/048079A1 |
Provided are: a method for predicting, at high accuracy and low cost, the production stability of a clone that produces a useful substance; an information processing device; a program; and a prediction model generation method. According ...
|
|
WO/2024/046394A1 |
Provided are a TIGIT and OX40-based strengthened receptor (TIGIT/OX40) capable of increasing the activation level and survival time of immune cells, and an immune cell modified to express the strengthened receptor. Also provided is an im...
|
|
WO/2024/048050A1 |
According to the present disclosure, provided is a carrier peptide fragment having excellent cell membrane permeability. The disclosed carrier peptide fragment comprises an amino acid sequence represented by SEQ ID NO: 1, KKRTLRKSNRKKR, ...
|
|
WO/2024/046393A1 |
Provided is a method for trans-differentiating non-neuronal cells of a mammal into neurons. The method comprises: providing a negative regulator capable of reducing the expression of negative regulatory genes, the negative regulatory gen...
|
|
WO/2024/050497A2 |
Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid- derived cells, and a multifluidic platform comprising at least one individually addressable...
|
|
WO/2024/048900A1 |
The present invention relates to a pharmaceutical composition for preventing or treating vascular dementia comprising glia-like cells differentiated from human mesenchymal stem cells (hMSC). The pharmaceutical composition of the present ...
|
|
WO/2024/046032A1 |
The present invention relates to ionic liquids based on non-natural amino acids, a preparation method therefor, and use thereof, and particularly provides a substance combination for preparing a protein containing non-natural amino acids...
|
|
WO/2024/048643A1 |
The purpose of the present invention is to provide an exosome production method which makes it possible to produce an exosome with high efficiency. The exosome production method comprises: a step for culturing a cell (12) using a cell fi...
|
|
WO/2024/046245A1 |
Disclosed are an anti-human PVRIG antibody or an antigen-binding fragment thereof, as well as an application thereof in the preparation of a medicament for treating diseases, such as cancer, which are related to the abnormal expression o...
|
|
WO/2024/048334A1 |
This protein comprises an amino acid sequence selected from the group consisting of amino acid sequences (a), (b), (c) and (d) and has a plasmalogen synthesis activity in a bacterium that expresses the protein. (a) The amino acid sequenc...
|
|
WO/2024/047368A1 |
This invention relates to expanded Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to increasing the number of CD16+ NK cells within ex...
|
|
WO/2024/046322A1 |
The present disclosure provides agonistic IL-15 complexes that have therapeutic use, and methods for making such proteins. The present disclosure additionally provides methods of treating disease in a subject in need thereof by administe...
|
|
WO/2024/048575A1 |
The present invention provides a novel substance that stably binds to a surface protein which is expressed in NK cells. The present invention provides a monobody that binds to a surface protein of NK cells and that has any one of amino a...
|
|
WO/2024/044850A1 |
Methods for inducing basal cell carcinoma (BCC) or BCC tumors, as well as an inducible non- human animal models of BCC, are defined herein. The methods and animal models comprise targeting Ptch1 and/or a tumor suppressor gene via conditi...
|
|
WO/2024/048688A1 |
The present disclosure provides an opsin that has a light cycle characteristic. Specifically, the present disclosure provides a protein including an amino acid sequence of an opsin, wherein the amino acid sequence of the opsin includes a...
|
|
WO/2024/047188A1 |
The invention relates to methods wherein extraembryonic mesodermal cells (EXCM) are isolated from cell cultures comprising trophoblast stem cells (TSC), by isolating CHD-1 negative EXCM cells from CHD-1 positive TSC.
|
|
WO/2024/048588A1 |
Provided is a novel cell culture system whereby it becomes possible to facilitate the efficiency of the culture of cells. The present invention is a cell culture system (S1) to which a plurality of cell culture devices (100, 200, 300) ar...
|
|
WO/2024/049773A1 |
Disclosed are alveolar organoids which recapitulate important aspects of in vivo lung epithelial regeneration, providing a tractable model to dissect regenerative processes. Clonal expansion of single AEPs generated complex alveolar orga...
|
|
WO/2024/043322A1 |
The present invention addresses the problem of providing: a method which is for producing targe viruses and by which the production amount of the viruses can be improved; and a culture composition containing animal cells, viruses, and a ...
|
|
WO/2024/041618A1 |
The present invention relates to an engineered immune cell co-expressing CD40L. In particular, the engineered immune cell of the present invention is a T cell or an NK cell. According to the present invention, a CAR molecule containing t...
|
|
WO/2024/042267A1 |
The method of the invention for production of a cell-cultured ingestion product comprises the steps of providing parts of a plant and pre-processing the parts in order to obtain a cell culture by cultivation of the cells as a cell suspen...
|
|
WO/2024/041650A1 |
Provided are anti-IL13RA2 single domain antibodies (e.g., VHH domain antibodies), and chimeric antigen receptors (CARs) that binds IL13RA2 comprising same in an extracellular antigen binding domain, a transmembrane domain, and an intrace...
|
|
WO/2024/043202A1 |
The present invention addresses the problem of providing: a method for introducing a nucleic acid into cells, wherein the method can efficiently introduce a high-concentration nucleic acid into high-density cells as a complex of the nucl...
|
|
WO/2024/040519A1 |
Provided is a method of intermittent perfusion fed-batch culture, comprising a fed-batch process including one or more intermittent perfusion phases during the middle to late stage to improve productivity and product quality.
|
|
WO/2024/040681A1 |
The present invention relates to an uPAR-targeted third-generation chimeric antigen receptor, immune effector cells (e.g., T cells, NK cells) engineered to express the chimeric antigen receptor of the present invention, and a use of the ...
|
|
WO/2024/044268A1 |
Methods and compositions for generating human pancreatic beta cells, and the progenitor cells thereof, from human pluripotent stem cells using chemically defined culture media are disclosed. The methods allow for the initial generation o...
|
